A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7068 (2006.01) A61K 31/245 (2006.01) A61K 31/353 (2006.01) A61K 31/405 (2006.01) A61K 31/502 (2006.01) A61K 31/706 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01)
Patent
CA 2725295
A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C- cyano-2-dioxy-.beta.-D-arabino-pentofuranosyl)-N4- palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-.beta.-D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-.beta.-D-arabino- pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.
Un premier aspect de linvention concerne une combinaison comprenant un inhibiteur dADN méthyltransférase et de 1-(2-C-cyano-2-dioxy-ß-D-arabino- pentofuranosyl)-N4-palmitoyl-cytosine ou de lun de ses métabolites. Un deuxième aspect de linvention concerne un produit pharmaceutique comprenant un inhibiteur dADN méthyltransférase et de la 1-(2-C-cyano-2-dioxy-ß-D- arabino-pentofuranosyl)-N4-palmitoyl-cytosine ou lun de ses métabolites, sous la forme dune combinaison préparée pour une utilisation simultanée, séquentielle ou séparée en thérapie. Un troisième aspect de linvention a pour objet un procédé de traitement dun trouble prolifératif, ledit procédé comprenant ladministration simultanée, séquentielle ou séparée dun inhibiteur dADN méthyltransférase et de 1-(2-C-cyano-2-dioxy-ß-D-arabino- pentofuranosyl)-N4-palmitoyl-cytosine ou de lun de ses métabolites, à un sujet.
Fleming Ian Neil
Green Simon Richard
Mackay Ruth
Cyclacel Limited
Sim & Mcburney
LandOfFree
Combination of spacitabine (cndac) and dna methyltransferase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of spacitabine (cndac) and dna methyltransferase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of spacitabine (cndac) and dna methyltransferase... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1714983